(Q42995627)

12 November 2017

title

Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease (English)

1 reference

12 November 2017

1 reference

Lirussi F

1

1 reference

12 November 2017

Beccarello A

2

1 reference

12 November 2017

Bortolato L

3

1 reference

12 November 2017

Morselli-Labate AM

4

1 reference

12 November 2017

Crovatto M

5

1 reference

12 November 2017

Ceselli S

6

1 reference

12 November 2017

Santini G

7

1 reference

12 November 2017

Crepaldi G

8

1 reference

12 November 2017

publication date

1 October 1999

1 reference

12 November 2017

1 reference

12 November 2017

volume

19

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

381-388

1 reference

A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Hepatitis C serotype and response to interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Factors predictive of a beneficial response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Effect of cholestasis and bile acids on interferon-induced 2',5'-adenylate synthetase and NK cell activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Intragastric administration of ursodeoxycholic acid suppresses immunoglobulin secretion by lymphocytes from liver, but not from peripheral blood, spleen or Peyer's patches in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

The monoethylglycinexylidide test for grading of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

Interferon for non-A, non-B chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00066.X

10.1111/J.1478-3231.1999.TB00066.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference